World’s first cancer stem cell model from iPS cells
Professor Seno points out that his group’s success lies in producing cancer stem cells from iPS cells, which when transplanted into nude mouse, retains the stem cell like properties overcoming the ethical issues.“CSCs from iPSCs and from mice also provides an abundant supply of many different kinds of cancer cells for experiments,” adds Professor Seno. “We are planning to produce a library of CSCs for customized cancer treatment.”
In the future Professor Seno is planning to collaborate with industrial partners to develop CSC libraries in the form of a consortium to manage cell libraries. The ready availability of CSCs would enable the establishment of novel systems to evaluate agents for cancer therapy “including those which were previously dropped by pharmaceutical companies”.
The research on cancer is an extension of Professor Seno’s expertise in the design of “functional physiologically and biologically active molecules for medicine and public health”. Other projects include the development of highly efficient, in vivo drug delivery systems (DDS) using nano-capsules of proteins or lipids to reduce side effects associated with conventional approaches; novel procedure for profiling tissues and cells for DDS; and design of novel mutant proteins of betacellulin (BTC) for the tissue regeneration therapy of pancreatic islets in diabetes therapy.
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.